{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:10:39Z","timestamp":1770329439872,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The aim of this study was to characterize the presence of ocular surface inflammation, using matrix metalloproteinase-9 (MMP-9) as a marker, on the ocular surface of eyes with implanted Boston keratoprosthesis type 1 (KPro).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with implanted KPro at a single tertiary center were recruited to assess ocular inflammation. MMP-9 was measured using the InflammaDry test in both eyes of each patient. The non-KPro eye served as the control. Rate of positivity of MMP-9 was compared between groups. Possible associations between ocular surface inflammation and the development of postoperative complications were evaluated using univariate statistical analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Fifty eyes from 25 patients were included. The mean age was 50 years. Noninflammatory indications for KPro were predominant among patients. Eighty-eight percent of KPro eyes had a positive test for MMP-9 while only 25% of control eyes were positive (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 001). The most common complications were retroprosthetic membrane, epithelial defects, and sterile corneal melt. The presence of a strong positive result was associated with a higher frequency of complications (80% of eyes) compared with a faint positive test (54%) and a negative test (33%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The KPro device seems to increase MMP-9 levels on the ocular surface. High MMP-9 levels may be associated with higher risk of complications. MMP-9 testing can be useful to assess subclinical ocular surface inflammation with a potential role in the postoperative care of patients with KPro.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coa.0000000000000008","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T17:00:41Z","timestamp":1680022841000},"page":"e0008","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Metalloproteinase-9 on the Ocular Surface of Patients With Implanted Boston Type 1 Keratoprosthesis"],"prefix":"10.1097","volume":"2","author":[{"given":"Andrea C.","family":"Arteaga","sequence":"first","affiliation":[{"name":"Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret C.","family":"Weiss","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Illinois at Chicago, Chicago, IL; and"},{"name":"College of Medicine, University of Illinois at Chicago, Chicago, IL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raiza","family":"Perez","sequence":"additional","affiliation":[{"name":"Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Soledad","family":"Cortina","sequence":"additional","affiliation":[{"name":"Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"R1-20241016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000358332","article-title":"Influence of primary diagnosis and complications on visual outcome in patients receiving a boston type 1 keratoprosthesis","volume":"52","author":"de Rezende Couto Nascimento","year":"2014","journal-title":"Ophthalmic Res."},{"key":"R2-20241016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/ICU.0000000000000373","article-title":"The Boston keratoprosthesis","volume":"28","author":"Saeed","year":"2017","journal-title":"Curr Opin Ophthalmol."},{"key":"R3-20241016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/ICU.0000000000000572","article-title":"Long-term outcomes of permanent keratoprosthesis","volume":"30","author":"Chhadva","year":"2019","journal-title":"Curr Opin Ophthalmol."},{"key":"R4-20241016","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.ophtha.2006.05.015","article-title":"Results from the multicenter boston type 1 keratoprosthesis study","volume":"113","author":"Zerbe","year":"2006","journal-title":"Ophthalmology"},{"key":"R5-20241016","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/IIO.0b013e318036bd8b","article-title":"Advances in Boston keratoprosthesis: enhancing retention and prevention of infection and inflammation","volume":"47","author":"Khan","year":"2007","journal-title":"Int Ophthalmol Clin."},{"key":"R6-20241016","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ophtha.2012.11.025","article-title":"Retention of the Boston keratoprosthesis type 1: multicenter study results","volume":"120","author":"Ciolino","year":"2013","journal-title":"Ophthalmology"},{"key":"R7-20241016","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/ICO.0000000000000893","article-title":"Tear matrix metalloproteinases and myeloperoxidase levels in patients with Boston keratoprosthesis type I","volume":"35","author":"Robert","year":"2016","journal-title":"Cornea"},{"key":"R8-20241016","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/ICO.0000000000000886","article-title":"Device retention, and complications","volume":"35","author":"Goins","year":"2016","journal-title":"Cornea"},{"key":"R9-20241016","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1074\/jbc.M107611200","article-title":"Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration","volume":"277","author":"Mohan","year":"2002","journal-title":"J Biol Chem."},{"key":"R10-20241016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/ICO.0000000000000175","article-title":"Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease","volume":"33","author":"Sambursky","year":"2014","journal-title":"Cornea"},{"key":"R11-20241016","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1167\/iovs.08-2476","article-title":"Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome","volume":"50","author":"Chotikavanich","year":"2009","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"R12-20241016","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/OPTH.S121256","article-title":"Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye","volume":"10","author":"Sambursky","year":"2016","journal-title":"Clin Ophthalmol."},{"key":"R13-20241016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jtos.2015.10.004","article-title":"The matrix metalloproteinase 9 point-of-care test in dry eye","volume":"14","author":"Lanza","year":"2016","journal-title":"Ocul Surf."},{"key":"R14-20241016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00003226-200101000-00003","article-title":"Keratoprosthesis: preoperative prognostic categories","volume":"20","author":"Yaghouti","year":"2001","journal-title":"Cornea"},{"key":"R15-20241016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ajo.2015.10.023","article-title":"Visual acuity outcomes of the boston keratoprosthesis type 1: multicenter study results","volume":"162","author":"Rudnisky","year":"2016","journal-title":"Am J Ophthalmol."},{"key":"R16-20241016","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2015.10.012","article-title":"Outcomes of repeat boston type 1 keratoprosthesis implantation","volume":"161","author":"Ahmad","year":"2016","journal-title":"Am J Ophthalmol."},{"key":"R17-20241016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jtos.2020.07.012","article-title":"Predictive factors of Boston type I keratoprosthesis outcomes: a long-term analysis","volume":"18","author":"Kanu","year":"2020","journal-title":"Ocul Surf."},{"key":"R18-20241016","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/09273948.2011.621580","article-title":"Clinical features and prognosis of Boston type I keratoprosthesis- associated corneal melt","volume":"19","author":"Utine","year":"2011","journal-title":"Ocul Immunol Inflamm."},{"key":"R19-20241016","first-page":"751","article-title":"The soft keratoprosthesis","volume":"95","author":"Caldwell","year":"1997","journal-title":"Trans Am Opthalmol Soc."},{"key":"R20-20241016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jconrel.2020.09.014","article-title":"Biofilm microenvironment activated supramolecular nanoparticles for enhanced photodynamic therapy of bacterial keratitis","volume":"327","author":"Han","year":"2020","journal-title":"J Control Release"},{"key":"R21-20241016","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.exer.2006.07.019","article-title":"Induction of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs correlates with outcome of acute experimental pseudomonal keratitis","volume":"83","author":"Ikema","year":"2006","journal-title":"Exp Eye Res."},{"key":"R22-20241016","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/ICO.0000000000000674","article-title":"Scanning electron microscopic analysis of biofilm formation in explanted human Boston type I keratoprostheses","volume":"35","author":"Sivaraman","year":"2016","journal-title":"Cornea"},{"key":"R23-20241016","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.3390\/cells9112450","article-title":"Corneal infection models: tools to investigate the role of biofilms in bacterial keratitis","volume":"9","author":"Urwin","year":"2020","journal-title":"Cells"},{"key":"R24-20241016","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/OPTH.S264984","article-title":"Ocular surface changes after switching from other prostaglandins to tafluprost and preservative-free tafluprost in glaucoma patients","volume":"14","author":"Ruangvaravate","year":"2020","journal-title":"Clin Ophthalmol."},{"key":"R25-20241016","doi-asserted-by":"crossref","first-page":"696328","DOI":"10.1155\/2013\/696328","article-title":"How ocular surface disease impacts the glaucoma treatment outcome","volume":"2013","author":"Ka\u0161telan","year":"2013","journal-title":"Biomed Res Int."},{"key":"R26-20241016","first-page":"1240537","article-title":"Extracellular MMP-9-based assessment of ocular surface inflammation in patients with primary open-angle glaucoma","volume":"2019","author":"Zaleska-Zmijewska","year":"2019","journal-title":"J Ophthalmol."},{"key":"R27-20241016","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/IIO.0b013e31827ab3d3","article-title":"The international use of the Boston type I keratoprosthesis","volume":"53","author":"Kim","year":"2013","journal-title":"Int Ophthalmol Clin."},{"key":"R28-20241016","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ophtha.2015.03.025","article-title":"Boston keratoprosthesis: outcomes and complications: a report by the American Academy of Ophthalmology","volume":"122","author":"Lee","year":"2015","journal-title":"Ophthalmology"},{"key":"R29-20241016","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jtos.2020.09.004","article-title":"Retroprosthetic membrane: a complication of keratoprosthesis with broad consequences","volume":"18","author":"Park","year":"2020","journal-title":"Ocul Surf."},{"key":"R30-20241016","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.ophtha.2014.05.030","article-title":"Long-term outcomes of Boston type 1 keratoprosthesis implantation: a retrospective multicenter cohort","volume":"121","author":"Srikumaran","year":"2014","journal-title":"Ophthalmology"}],"container-title":["Cornea Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/coa.0000000000000008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T23:00:26Z","timestamp":1729119626000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/coa.0000000000000008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/coa.0000000000000008","relation":{},"ISSN":["2833-6992"],"issn-type":[{"value":"2833-6992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2022-11-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}